ClinicalTrials.gg
TerminatedNCT04336982Updated May 31, 2024

A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia

A Phase 1 interventional study of CC-90009 and Venetoclax in Leukemia, Myeloid, Acute, sponsored by Celgene. Terminated at 14 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-31.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

Why this study was terminated
Business objectives have changed.

From the registry’s dates

  • Primary completion was Oct 2023, 3 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing gilteritinib in Leukemia, Myeloid, Acute — 13 open to participants now, 15 under way, 6 of them phase 3. gilteritinib · Leukemia, Myeloid, Acute.

Enrollment
26th of 31
22 · median 97
Started
2020
with 2 others
Phase 1
6 of 31
1 open now
Registered
19th of 31
by date
Lead sponsor
1 of 31
Celgene

Among the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute, this one is the 26th largest by enrollment, is one of 3 that started in 2020, is one of 6 in phase 1, and was the 19th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

13 of the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About gilteritinib

gilteritinib: first FDA approval 2018 (XOSPATA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing gilteritinib in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

CC-90009-AML-002 is an exploratory Phase 1b, open-label, multi-arm trial to evaluate the safety and efficacy of CC-90009 in combination with anti-leukemia agents in participants with acute myeloid leukemia (AML).

Read the detailed description

Study CC-90009-AML-002 is an open-label, multi-arm, parallel multi-cohort, multicenter, Phase 1b study to determine the safety, tolerability, PK, and efficacy of CC 90009 in combination with anti-leukemia agents used for the treatment of AML. CC 90009 will be given as a combination therapy to subjects with newly diagnosed (ND) or relapsed or refractory (R/R) AML.

The dose and schedule finding part (Part A) of the study will evaluate the safety, PK and PD data, and preliminary efficacy information and determine the Part B dose and schedule for each arm.

The expansion part (Part B) of the study will further evaluate the safety and efficacy of the CC-90009 containing combination at or below the maximum tolerated dose (MTD) in the selected cohorts in order to determine the recommended Phase 2 dose (RP2D) for subjects with AML.

03

Conditions studied

  • Leukemia, Myeloid, Acute

Keywords

  • CC-90009
  • Venetoclax
  • Azacitidine
  • Gilteritinib
  • Hematologic cancers
  • Leukemia
  • Acute myeloid leukemia
  • AML
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.
  2. Arm A (CC-90009 + venetoclax/azacitidine):

    1. Part A: Newly diagnosed AML with poor/adverse risk genetic abnormalities and is either ≥ 75 years of age or is ineligible for intensive chemotherapy OR
    2. Part A: Primary AML, or AML in first relapse, and is ≥ 18 years of age
    3. Part B: Newly diagnosed AML and is ≥ 75 years of age or intensive chemotherapy ineligible
  3. Arm B (CC-90009 + gilteritinib):

    1. Subject is ≥ 18 years of age.
    2. Fms-like tyrosine kinase 3 (FLT3) mutation positive.
    3. Gilteritinib treatment naïve
  4. Subject has (ECOG) performance status of 0, 1 or 2.
  5. Subject must have the following screening laboratory values:

    • Total White Blood Cell count (WBC) \< 25 x 10\^9/L prior to study treatments. Treatment with hydroxyurea to achieve this level is allowed.
    • Selected electrolytes within normal limits or correctable with supplements.

      • Participant must have adequate liver function as demonstrated by: (AST) and alanine aminotransferase (ALT) ≤ 2.5 x (ULN) and ≤ 1.5 x ULN
      • Participant has adequate renal function as demonstrated by an estimated serum of ≥ 30 mL/min.
  6. Agree to follow the CC-90009 Pregnancy Prevention Plan (PPP) and combination agents' requirements.

Exclusion criteria

Exclusion Criteria:

  1. Subject with acute promyelocytic leukemia (APL)
  2. Subject has received systemic anticancer therapy (including therapy) or radiotherapy \< 28 days or 5 half-lives, whichever is shorter, prior to the start of study treatment
  3. Patients with prior hematopoietic stem cell transplant (HSCT) who, in the investigator's judgment, have not fully recovered from the effects of the last transplant (eg, transplant related side effects)
  4. Prior allogeneic HSCT with either standard or reduced intensity conditioning ≤ 6 months prior to dosing
  5. Subject on systemic therapy post HSCT at the time of screening, or with (GVHD). The use of topical for ongoing skin or ocular GVHD is permitted
  6. Subject has persistent, clinically significant non-hematologic toxicities from prior therapies which have not recovered to \< Grade 2
  7. Subject has or is suspected of having central nervous system (CNS) leukemia. Evaluation of cerebrospinal fluid is only required if CNS involvement by leukemia is suspected during screening.
  8. Disorders or conditions disrupting normal calcium homeostasis or preventing calcium supplementation.
  9. Impaired cardiac function or clinically significant cardiac diseases, including any of the following:

    1. (LVEF) \< 45% as determined by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO).
    2. Complete left bundle branch or bifascicular block.
    3. Congenital long syndrome.
    4. Persistent or clinically meaningful ventricular arrhythmias.
    5. QTcF ≥ 470 ms (Arm A) or > 450 ms (Arm B) on Screening (ECG)
    6. Unstable angina pectoris or myocardial infarction ≤ 6 months prior to starting study treatments or unstable arrhythmia.
    7. Cardiovascular disability status of Class ≥2. Class 2 is defined as cardiac disease in which patients are comfortable at rest but ordinary physical activity results in fatigue, palpitations, dyspnea, or anginal pain.
  10. Subject is a pregnant or lactating female
  11. Additional exclusion criteria based on combination agent:

    a. For Combination Arm A (venetoclax/azacitidine):

    • Received strong or moderate inhibitors or inducers or P-gp inhibitors within 7 days prior to initiation of first venetoclax dose.
    • Subject has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges), or Star fruit within 3 days prior to first venetoclax dose through last dose of venetoclax.
  12. Previous SARS-CoV-2 infection within 10 days for mild or asymptomatic infections or 20 days for severe/critical illness prior to C1D1.

    a. Acute symptoms must have resolved and based on investigator assessment in consultation with the medical monitor, there are no sequelae that would place the participant at a higher risk of receiving study treatment.

  13. Previous SARS-CoV-2 vaccine within 14 days of C1D1.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    CC-90009 in combination with venetoclax and azacitidine

    CC-90009 will be administered intravenously per dosing schedule in a 28-day cycle. Venetoclax will be administered orally QD. Azacitidine will be administered intravenously or subcutaneously on planned dosing days for each cycle.

    Drug: CC-90009 · Drug: Venetoclax · Drug: Azacitidine

  • Experimental
    CC-90009 in combination with gilteritinib

    CC-90009 will be administered intravenously per dosing schedule in a 28-day cycle. Gilteritinib will be administered orally QD.

    Drug: Gilteritinib

Interventions

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicity (DLT)

    Number of participants with a DLT

    Time frame: Up to 28 days

  2. Adverse Events (AEs)

    An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology.

    Time frame: Up to 28 days after last dose of study drug.

Secondary outcomes

  1. Complete Remission Rate (CRR),

    is defined as the rate for any type of CR or CRh

    Time frame: Up to 3 years

  2. Objective Response Rate (ORR)

    includes all responses of complete remissions (CRs), Morphologic leukemia-free state (MLFS), and Partial remission (PR)

    Time frame: Up to 3 years

  3. Progression Free Survival (PFS)

    is defined as the time from the first dose of study drug(s) to the first occurrence of relapse or progression or death from any cause

    Time frame: Up to 3 years

  4. Overall Survival (OS)

    is measured as the time from the first dose of study drug(s) to death due to any cause and will be analyzed in a manner similar to that described for PFS.

    Time frame: Up to 3 years

  5. Duration of Remission

    is measured from the time when criteria for CR/CRh/PR are first met (whichever is first recorded) until the first date at which relapse, or progressive disease is objectively documented.

    Time frame: Up to 3 years

  6. Time to Remission

    is measured from the time when criteria for CR/CRh/PR are first met (whichever is first recorded)

    Time frame: Up to 3 years

  7. Pharmacokinetics - Cmax

    observed maximum concentration in plasma

    Time frame: Until last CC-90009 dose in Cycle 3 (each cycle is 28 days. CC-90009 dosing days are Days 1-5 in Cycle 3)

  8. Pharmacokinetics - AUC24

    area under the plasma concentration time-curve from time 0 to 24 hours postdose

    Time frame: Until last CC-90009 dose in Cycle 3 (each cycle is 28 days. CC-90009 dosing days are Days 1-5 in Cycle 3)

  9. Pharmacokinetics - t1/2

    terminal half life

    Time frame: Until last CC-90009 dose in Cycle 3 (each cycle is 28 days. CC-90009 dosing days are Days 1-5 in Cycle 3)

07

Study locations

14 sites
  • Local Institution - 104
    San Francisco, California 94143-0324, United States
  • Local Institution - 107
    New Haven, Connecticut 06510, United States
  • Local Institution - 103
    Boston, Massachusetts 02115, United States
  • Local Institution - 101
    Saint Louis, Missouri 63110, United States
  • Local Institution - 108
    Hackensack, New Jersey 07601, United States
  • Local Institution - 105
    Houston, Texas 77030-4009, United States
  • Local Institution - 102
    Seattle, Washington 98109-1024, United States
  • Local Institution - UNK3
    Yvoir, 5530, Belgium
  • Local Institution - 202
    Edmonton, Alberta T6G 2R7, Canada
  • Local Institution - 201
    Toronto, Ontario M5G 2M9, Canada
  • Local Institution - 402
    Marseille, 13273, France
  • Local Institution - 401
    Pessac Cedex, 33604, France
  • Local Institution - 404
    Toulouse Cedex 9, 31059, France
  • Local Institution - 301
    Oxford, OX3 9DU, United Kingdom
08

References and documents

Publications

  • Surka C, Jin L, Mbong N, Lu CC, Jang IS, Rychak E, Mendy D, Clayton T, Tindall E, Hsu C, Fontanillo C, Tran E, Contreras A, Ng SWK, Matyskiela M, Wang K, Chamberlain P, Cathers B, Carmichael J, Hansen J, Wang JCY, Minden MD, Fan J, Pierce DW, Pourdehnad M, Rolfe M, Lopez-Girona A, Dick JE, Lu G. CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells. Blood. 2021 Feb 4;137(5):661-677. doi: 10.1182/blood.2020008676. PubMed 33197925 ↗

Individual participant data

Plan to share: Yes — Information relating to our policy on data sharing and the process for requesting data can be found at the following link: https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.celgene.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Oct 2023, 38 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2020
First posted
Apr 7, 2020
StartActual
Aug 5, 2020
Primary completionActual
Oct 25, 2023
CompletionActual
Apr 5, 2024
Last update
May 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04336982
Lead sponsor
Celgene
Collaborators
AbbVie
Responsible party
Sponsor
First posted
Apr 7, 2020
Start date
Aug 5, 2020
Primary completion
Oct 25, 2023
Completion
Apr 5, 2024
Last update
May 31, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: CC-90009 · Gilteritinib

Start the discussion